SEC Form 4 · accession 0000899243-18-017778

Eidos Therapeutics, Inc. · EIDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Jun 22, 2018

Accepted (ET)

Jun 22, 2018 · 6:56 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001731831

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Jun 22, 2018	C	18,826,417	$0.00	A	18,826,417	I	See footnote
Common Stock^F2	Jun 22, 2018	F	211,762	$17.00	D	18,614,655	I	See footnote
Common Stock^F2	Jun 22, 2018	P	1,000,000	$17.00	A	19,614,655	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrants^F2,F1	$10.8348	Jun 22, 2018	X	332,262	D	—	—	Series B Preferred Stock	332,262	0	I
Series B Convertible Preferred Stock^F2,F3	—	Jun 22, 2018	X	332,262	A	—	—	Common Stock	397,385	2,909,029	I
Series B Convertible Preferred Stock^F2,F3	—	Jun 22, 2018	C	2,909,029	D	—	—	Common Stock	3,479,198	0	I
Series Seed Preferred Stock^F2,F3	—	Jun 22, 2018	C	12,832,123	D	—	—	Common Stock	15,347,219	0	I

F1Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.
F2The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
F3Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.